Progenics (PGNX) volatility elevated into FDA approval of constipation treatment

Progenics Pharma (NASDAQ: PGNX) August call option implied volatility is at 177, September is at 133; compared to its 52-week range of 57 to 173 into Valeant Pharmaceuticals International (VALEANT) and Progenics Pharmaceuticals announced that the FDA has approved RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

You May Also Be Interested In

• SpaceX (SPCX) call put ratio 2 calls to 1 put as share price at $160
• Meta Platforms (META) call put ratio 3.9 calls to 1 put with a focus on August 720 calls as share price up 8.8%
• Sandisk (SNDK) call put ratio 1.2 calls to 1 put as share price down 10.5%